The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
The Effect of Cilazapril, a New Angiotensin Converting Enzyme Inhibitor, on Peak and Trough Blood Pressure Measurements in Hypertensive Patients
Cilazapril ( CLZ ) is a new , long-acting nonsulfhydril converting enzyme inhibitor ( ACE-I ) . Its effect on peak and trough sitting diastolic blood pressure ( SDBP ) was studied in a total of 85 patients with uncomplicated , essential hypertension at three centers . After 4 weeks of a single-blind placebo ( PLA ) run-in period , patients whose SDBP was between 100 and 115 mm Hg , were r and omized into active treatment with either PLA ( n = 27 ) , CLZ 2.5 mg ( n = 29 ) , or CLZ 5 mg ( n = 29 ) once daily in a double-blind fashion for another 8 weeks . At the end of the PLA run-in and after 4 and 8 weeks active therapy , an hourly blood pressure ( BP ) profile during 1–10 and 21–24 h postdose was performed . The drop in SDBP at the end of the active treatment period at peak and trough was statistically and clinical ly significant for both CLZ doses in comparison with the PLA group . The peak/trough ratio after substraction of the PLA effect was 62 % for CLZ 2.5 mg and 59 % for CLZ 5 mg . These results indicate that the dose regimen of CLZ 2.5–5 mg once daily is adequate and effective for 24
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .